Saturday, 26 December 2009

Diflucan


Diflucan is a brand name of fluconazole, approved by the FDA in the following formulation(s):


DIFLUCAN (fluconazole - for suspension; oral)



  • Manufacturer: PFIZER

    Approval date: December 23, 1993

    Strength(s): 200MG/5ML [RLD][AB], 50MG/5ML [AB]

DIFLUCAN (fluconazole - tablet; oral)



  • Manufacturer: PFIZER

    Approval date: January 29, 1990

    Strength(s): 100MG [AB], 200MG [RLD][AB], 50MG [AB]


  • Manufacturer: PFIZER

    Approval date: June 30, 1994

    Strength(s): 150MG [AB]

Has a generic version of Diflucan been approved?


Yes. The following products are equivalent to Diflucan:


fluconazole for suspension; oral



  • Manufacturer: AUROBINDO PHARM

    Approval date: September 18, 2009

    Strength(s): 200MG/5ML [AB], 50MG/5ML [AB]


  • Manufacturer: IVAX SUB TEVA PHARMS

    Approval date: September 12, 2007

    Strength(s): 200MG/5ML [AB], 50MG/5ML [AB]


  • Manufacturer: RANBAXY

    Approval date: July 29, 2004

    Strength(s): 200MG/5ML [AB], 50MG/5ML [AB]


  • Manufacturer: ROXANE

    Approval date: July 29, 2004

    Strength(s): 200MG/5ML [AB], 50MG/5ML [AB]


  • Manufacturer: TARO PHARM INDS

    Approval date: December 18, 2006

    Strength(s): 200MG/5ML [AB], 50MG/5ML [AB]

fluconazole tablet; oral



  • Manufacturer: AMNEAL PHARM

    Approval date: March 7, 2011

    Strength(s): 100MG [AB], 150MG [AB], 200MG [AB], 50MG [AB]


  • Manufacturer: APOTEX

    Approval date: July 29, 2004

    Strength(s): 100MG [AB], 150MG [AB], 200MG [AB], 50MG [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: October 7, 2008

    Strength(s): 100MG [AB], 150MG [AB], 200MG [AB], 50MG [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: January 25, 2006

    Strength(s): 100MG [AB], 150MG [AB], 200MG [AB], 50MG [AB]


  • Manufacturer: IVAX SUB TEVA PHARMS

    Approval date: July 29, 2004

    Strength(s): 100MG [AB], 150MG [AB], 200MG [AB], 50MG [AB]


  • Manufacturer: MYLAN

    Approval date: July 29, 2004

    Strength(s): 100MG [AB], 100MG [AB], 150MG [AB], 150MG [AB], 200MG [AB], 200MG [AB], 50MG [AB], 50MG [AB]


  • Manufacturer: RANBAXY

    Approval date: July 29, 2004

    Strength(s): 100MG [AB], 150MG [AB], 200MG [AB], 50MG [AB]


  • Manufacturer: TARO

    Approval date: July 29, 2004

    Strength(s): 100MG [AB], 150MG [AB], 200MG [AB], 50MG [AB]


  • Manufacturer: TEVA

    Approval date: July 29, 2004

    Strength(s): 100MG [AB], 150MG [AB], 200MG [AB], 50MG [AB]


  • Manufacturer: UNIQUE PHARM LABS

    Approval date: September 28, 2005

    Strength(s): 100MG [AB], 200MG [AB], 50MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Diflucan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Diflucan.

See also...

  • Diflucan Consumer Information (Drugs.com)
  • Diflucan Consumer Information (Wolters Kluwer)
  • Diflucan Single-Dose Tablets Consumer Information (Wolters Kluwer)
  • Diflucan Solution Consumer Information (Wolters Kluwer)
  • Diflucan Suspension Consumer Information (Wolters Kluwer)
  • Diflucan Consumer Information (Cerner Multum)
  • Diflucan Advanced Consumer Information (Micromedex)
  • Diflucan IV Advanced Consumer Information (Micromedex)
  • Diflucan Intravenous Advanced Consumer Information (Micromedex)
  • Diflucan AHFS DI Monographs (ASHP)
  • Fluconazole Consumer Information (Wolters Kluwer)
  • Fluconazole Single-Dose Tablets Consumer Information (Wolters Kluwer)
  • Fluconazole Solution Consumer Information (Wolters Kluwer)
  • Fluconazole Suspension Consumer Information (Wolters Kluwer)
  • Fluconazole Consumer Information (Cerner Multum)
  • CanesOral Advanced Consumer Information (Micromedex)
  • Fluconazole Advanced Consumer Information (Micromedex)
  • Fluconazole Intravenous Advanced Consumer Information (Micromedex)
  • Fluconazole AHFS DI Monographs (ASHP)
at No comments:

Sunday, 20 December 2009

Teicoplanina Northia




Teicoplanina Northia may be available in the countries listed below.


Ingredient matches for Teicoplanina Northia



Teicoplanin

Teicoplanin is reported as an ingredient of Teicoplanina Northia in the following countries:


  • Argentina

International Drug Name Search

at No comments:

Wednesday, 16 December 2009

Céfotaxime G Gam




Céfotaxime G Gam may be available in the countries listed below.


Ingredient matches for Céfotaxime G Gam



Cefotaxime

Cefotaxime sodium salt (a derivative of Cefotaxime) is reported as an ingredient of Céfotaxime G Gam in the following countries:


  • France

International Drug Name Search

at No comments:

Sunday, 13 December 2009

Novolizer Formoterol




Novolizer Formoterol may be available in the countries listed below.


Ingredient matches for Novolizer Formoterol



Formoterol

Formoterol fumarate dihydrate (a derivative of Formoterol) is reported as an ingredient of Novolizer Formoterol in the following countries:


  • Austria

  • Belgium

  • Luxembourg

International Drug Name Search

at No comments:

Wednesday, 9 December 2009

Xolegel


Xolegel is a brand name of ketoconazole topical, approved by the FDA in the following formulation(s):


XOLEGEL (ketoconazole - gel; topical)



  • Manufacturer: AQUA PHARMS

    Approval date: July 28, 2006

    Strength(s): 2% [RLD]

Has a generic version of Xolegel been approved?


No. There is currently no therapeutically equivalent version of Xolegel available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xolegel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Anhydrous topical skin preparations
    Patent 7,179,475
    Issued: February 20, 2007
    Inventor(s): Burnett; Katherine M. & Kurtz; Ellen S.
    Assignee(s): Johnson & Johnson Consumer Companies, Inc.
    The present invention provides anhydrous compositions for topical delivery of a medicament comprising (A) a penetration enhancer/solvent selected from the group consisting of alcohol, propylene glycol, or a combination thereof; (B) a humectant/solvent selected from the group consisting of polyethylene glycol, glycerin, sorbitol, xylitol, or any combination of any of the foregoing; and (C) an anhydrous vehicle. In an alternate embodiment, the present invention provides anhydrous compositions for topical delivery of a medicament which comprise (A) a penetration enhancer/solvent selected from the group consisting of alcohol, propylene glycol, or a combination thereof; (B) a humectant/solvent selected from the group consisting of polyethylene glycol, glycerin, sorbitol, xylitol or any combination of any of the foregoing; (C) an anhydrous vehicle; and (D) a medicament. Also provided are methods for topically delivering a medicament to an animal, such as a mammal or a human patient, in need of the medicament by topically administering to the animal the compositions of the present invention.
    Patent expiration dates:

    • December 4, 2018
      ✓ 
      Patent use: TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS
      ✓ 
      Drug product



See also...

  • Xolegel Consumer Information (Drugs.com)
  • Xolegel Gel Consumer Information (Wolters Kluwer)
  • Xolegel Consumer Information (Cerner Multum)
  • Xolegel Topical Advanced Consumer Information (Micromedex)
  • Ketoconazole Cream Consumer Information (Wolters Kluwer)
  • Ketoconazole Foam Consumer Information (Wolters Kluwer)
  • Ketoconazole Gel Consumer Information (Wolters Kluwer)
  • Ketoconazole Shampoo Consumer Information (Wolters Kluwer)
  • Ketoconazole topical Consumer Information (Cerner Multum)
  • Ketoderm Topical Advanced Consumer Information (Micromedex)
  • Ketoconazole Topical Advanced Consumer Information (Micromedex)
  • Ketoconazole topical AHFS DI Monographs (ASHP)
at No comments:

Tuesday, 8 December 2009

Monedax




Monedax may be available in the countries listed below.


Ingredient matches for Monedax



Epalrestat

Epalrestat is reported as an ingredient of Monedax in the following countries:


  • Japan

International Drug Name Search

at No comments:

Monday, 7 December 2009

VisionBlue


VisionBlue is a brand name of trypan blue ophthalmic, approved by the FDA in the following formulation(s):


VISIONBLUE (trypan blue - solution; ophthalmic)



  • Manufacturer: DORC

    Approval date: December 16, 2004

    Strength(s): 0.06% [RLD]

Has a generic version of VisionBlue been approved?


No. There is currently no therapeutically equivalent version of VisionBlue available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of VisionBlue. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with VisionBlue.

See also...

  • VisionBlue Advanced Consumer Information (Micromedex)
  • Vision Blue Consumer Information (Drugs.com)
  • Trypan blue Intraocular Advanced Consumer Information (Micromedex)
at No comments:

Friday, 4 December 2009

Elocon


Elocon is a brand name of mometasone topical, approved by the FDA in the following formulation(s):


ELOCON (mometasone furoate - cream; topical)



  • Manufacturer: SCHERING

    Approval date: May 6, 1987

    Strength(s): 0.1% [RLD][AB]

ELOCON (mometasone furoate - lotion; topical)



  • Manufacturer: SCHERING

    Approval date: March 30, 1989

    Strength(s): 0.1% [RLD][AB]

ELOCON (mometasone furoate - ointment; topical)



  • Manufacturer: SCHERING

    Approval date: April 30, 1987

    Strength(s): 0.1% [RLD][AB]

Has a generic version of Elocon been approved?


Yes. The following products are equivalent to Elocon:


mometasone furoate cream; topical



  • Manufacturer: FOUGERA PHARMS

    Approval date: April 8, 2005

    Strength(s): 0.1% [AB]


  • Manufacturer: G AND W LABS

    Approval date: May 22, 2006

    Strength(s): 0.1% [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: May 28, 2008

    Strength(s): 0.1% [AB]


  • Manufacturer: TARO

    Approval date: December 21, 2004

    Strength(s): 0.1% [AB]


  • Manufacturer: TOLMAR

    Approval date: April 18, 2007

    Strength(s): 0.1% [AB]

mometasone furoate lotion; topical



  • Manufacturer: FOUGERA PHARMS

    Approval date: November 29, 2007

    Strength(s): 0.1% [AB]


  • Manufacturer: G AND W LABS

    Approval date: November 21, 2007

    Strength(s): 0.1% [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: August 9, 2010

    Strength(s): 0.1% [AB]


  • Manufacturer: PERRIGO

    Approval date: April 6, 2005

    Strength(s): 0.1% [AB]


  • Manufacturer: TARO

    Approval date: March 15, 2006

    Strength(s): 0.1% [AB]


  • Manufacturer: TOLMAR

    Approval date: November 21, 2007

    Strength(s): 0.1% [AB]

mometasone furoate ointment; topical



  • Manufacturer: FOUGERA PHARMS

    Approval date: March 28, 2005

    Strength(s): 0.1% [AB]


  • Manufacturer: G AND W LABS

    Approval date: June 20, 2006

    Strength(s): 0.1% [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: May 28, 2008

    Strength(s): 0.1% [AB]


  • Manufacturer: PERRIGO NEW YORK

    Approval date: March 18, 2002

    Strength(s): 0.1% [AB]


  • Manufacturer: TARO

    Approval date: December 3, 2004

    Strength(s): 0.1% [AB]


  • Manufacturer: TOLMAR

    Approval date: November 14, 2003

    Strength(s): 0.1% [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Elocon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Elocon.

See also...

  • Elocon Consumer Information (Drugs.com)
  • Elocon Cream Consumer Information (Wolters Kluwer)
  • Elocon Lotion Consumer Information (Wolters Kluwer)
  • Elocon Consumer Information (Cerner Multum)
  • Elocon Advanced Consumer Information (Micromedex)
  • Elocon topical AHFS DI Monographs (ASHP)
  • Mometasone Cream Consumer Information (Wolters Kluwer)
  • Mometasone Lotion Consumer Information (Wolters Kluwer)
  • Mometasone topical Consumer Information (Cerner Multum)
  • Elocom Advanced Consumer Information (Micromedex)
  • Pms-Mometasone Advanced Consumer Information (Micromedex)
  • Mometasone Topical application Advanced Consumer Information (Micromedex)
  • Mometasone Furoate topical AHFS DI Monographs (ASHP)
at No comments:

Thursday, 26 November 2009

Simchol




Simchol may be available in the countries listed below.


Ingredient matches for Simchol



Simvastatin

Simvastatin is reported as an ingredient of Simchol in the following countries:


  • Indonesia

International Drug Name Search

at No comments:

Sunday, 22 November 2009

Oxacilline




Oxacilline may be available in the countries listed below.


Ingredient matches for Oxacilline



Oxacillin

Oxacilline (DCF) is known as Oxacillin in the US.

International Drug Name Search

Glossary

DCFDénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.
at No comments:

Liotixil




Liotixil may be available in the countries listed below.


Ingredient matches for Liotixil



Ceftazidime

Ceftazidime pentahydrate (a derivative of Ceftazidime) is reported as an ingredient of Liotixil in the following countries:


  • Italy

International Drug Name Search

at No comments:

Saturday, 21 November 2009

Varimer




Varimer may be available in the countries listed below.


Ingredient matches for Varimer



Mercaptopurine

Mercaptopurine monohydrate (a derivative of Mercaptopurine) is reported as an ingredient of Varimer in the following countries:


  • Argentina

International Drug Name Search

at No comments:

Lidoderm


Lidoderm is a brand name of lidocaine topical, approved by the FDA in the following formulation(s):


LIDODERM (lidocaine - patch; topical)



  • Manufacturer: TEIKOKU PHARMA USA

    Approval date: March 19, 1999

    Strength(s): 5% [RLD]

Has a generic version of Lidoderm been approved?


No. There is currently no therapeutically equivalent version of Lidoderm available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lidoderm. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine
    Patent 5,411,738
    Issued: May 2, 1995
    Inventor(s): Hind; Harry
    Assignee(s): Hind Health Care, Inc.
    Methods and compositions are offered for reducing nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia), where intradermal delivery of lidocaine is maintained for a predetermined period of time. The lidocaine appears to specifically affect the damaged nerve fibers, while leaving the undamaged and normal nerve fibers with retention of response to other stimuli. Lidocaine formulations are provided which allow for the necessary dosage of the lidocaine in the dermis during the period of treatment. The formulation may be covered with an occlusive or non-occlusive dressing, which protects the lidocaine formulation from mechanical removal and enhances the transport of the lidocaine into the dermis. Long term relief is realized after maintenance of the administration of lidocaine has been terminated.
    Patent expiration dates:

    • May 2, 2012




  • Method for treating pain associated with herpes-zoster and post-herpetic neuralgia
    Patent 5,601,838
    Issued: February 11, 1997
    Inventor(s): Hind; Harry
    Assignee(s): Hind Health Care, Inc.
    A method is offered for reducing the pain associated with herpes-zoster and post-herpetic neuralgia. The method consists of administering a composition incorporating a transdermal delivery system for the administration of Lidocaine to areas of the body afflicted by herpes-zoster and post-herpetic neuralgia enclosed with an occlusive dressing or a plaster dressing.
    Patent expiration dates:

    • May 2, 2012
      ✓ 
      Patent use: METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA




  • Adhesive patch for applying analgesic medication to the skin
    Patent 5,741,510
    Issued: April 21, 1998
    Inventor(s): Rolf; David & Sjoblom Urmann; Elisabeth K.
    Assignee(s): Lectec Corporation
    A medication patch to be applied to the skin includes a self-supporting backing layer to give the patch the required integrity and strength by acting as a supporting framework for other components, and a flexible hydrophilic pressure-sensitive adhesive reservoir comprising a natural or synthetic polymer for the sustained release of medication to be absorbed topically through the skin into the body of a patient. The reservoir has two portions: first, an external coating layer with an exposed lower skin-contacting surface that forms a pressure-sensitive bond with the skin, and second, an upper internal portion which infiltrates the porous backing and becomes solidified therein after being applied so that the reservoir and the backing are unified, enabling the backing itself to act as a storage location for the medication-containing reservoir. The medication within the reservoir migrates over time from within the backing through the lower coating layer and passes through the skin to provide sustained release of the medication into the body of a patient.
    Patent expiration dates:

    • March 30, 2014
      ✓ 
      Drug product




  • External preparation for application to the skin containing lidocaine
    Patent 5,827,529
    Issued: October 27, 1998
    Inventor(s): Ono; Masahiro & Akazawa; Mitsuji & Seki; Michiko & Iwamoto; Kiyomi & Konishi; Ryoji
    Assignee(s): Teikoku Seiyaku Kabushiki Kaisha
    An external preparation for application to the skin containing lidocaine which comprises a drug-retaining layer placed on a support, wherein said drug-retaining layer comprises an adhesive gel base and 1 to 10% by weight of lidocaine, said base comprising a water-soluble high molecular weight substance, water and a water-retaining agent, which can release the active lidocaine gradually and constantly so that lidocaine is transdermally absorbed for a long period of time.
    Patent expiration dates:

    • October 27, 2015
      ✓ 
      Patent use: EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE



See also...

  • Lidoderm Consumer Information (Drugs.com)
  • Lidoderm Patch Consumer Information (Wolters Kluwer)
  • Lidoderm Consumer Information (Cerner Multum)
  • Lidoderm Topical application Advanced Consumer Information (Micromedex)
  • Lidocaine Aerosol Consumer Information (Wolters Kluwer)
  • Lidocaine Cream Consumer Information (Wolters Kluwer)
  • Lidocaine Foam Consumer Information (Wolters Kluwer)
  • Lidocaine Gel Consumer Information (Wolters Kluwer)
  • Lidocaine Intradermal System Consumer Information (Wolters Kluwer)
  • Lidocaine Liquid Consumer Information (Wolters Kluwer)
  • Lidocaine Lotion Consumer Information (Wolters Kluwer)
  • Lidocaine Ointment Consumer Information (Wolters Kluwer)
  • Lidocaine Patch Consumer Information (Wolters Kluwer)
  • Lidocaine Solution Consumer Information (Wolters Kluwer)
  • Xylocaine Solution Consumer Information (Wolters Kluwer)
  • Zilactin L Liquid Consumer Information (Wolters Kluwer)
  • Zilactin-L Consumer Information (Cerner Multum)
  • Lidocaine topical Consumer Information (Cerner Multum)
  • Burn-O-Jel Topical application Advanced Consumer Information (Micromedex)
  • Burnamycin Topical application Advanced Consumer Information (Micromedex)
  • Solarcaine First Aid Lidocaine Spray Topical application Advanced Consumer Information (Micromedex)
  • Solarcaine Lidocaine First Aid Spray Topical application Advanced Consumer Information (Micromedex)
  • Xylocaine Topical application Advanced Consumer Information (Micromedex)
  • Lidocaine Topical application Advanced Consumer Information (Micromedex)
at No comments:

Thursday, 19 November 2009

Nesacaine-MPF


See also: Generic Nesacaine


Nesacaine-MPF is a brand name of chloroprocaine, approved by the FDA in the following formulation(s):


NESACAINE-MPF (chloroprocaine hydrochloride - injectable; injection)



  • Manufacturer: APP PHARMS

    Approval date: May 2, 1996

    Strength(s): 2% [RLD][AP], 3% [RLD][AP]

Has a generic version of Nesacaine-MPF been approved?


Yes. The following products are equivalent to Nesacaine-MPF:


chloroprocaine hydrochloride injectable; injection



  • Manufacturer: BEDFORD

    Approval date: September 9, 1998

    Strength(s): 2% [AP], 3% [AP]


  • Manufacturer: HOSPIRA

    Approval date: April 16, 1982

    Strength(s): 2% [AP], 3% [AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nesacaine-MPF. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Nesacaine-MPF.

See also...

    at No comments:

    Interferon omega




    In some countries, this medicine may only be approved for veterinary use.

    Therapeutic Categories

    Antiviral agent

    Biological response modifier, BRM

    Immunostimulant

    Chemical Name

    recombinant interferon omega, feline origin

    Foreign Names

    • Interferon omega (German)
    • Interféron oméga (French)

    Generic Name

    • IFN Omega (IS)

    Brand Names

    • Virbagen (veterinary use)
      Biofarm, Finland; Virbac, Australia; Virbac, Belgium; Virbac, Switzerland; Virbac, Germany; Virbac, France; Virbac, Italy; Virbac, New Zealand

    International Drug Name Search

    Glossary

    ISInofficial Synonym

    Click for further information on drug naming conventions and International Nonproprietary Names.
    at No comments:

    Tuesday, 17 November 2009

    Magnespasmyl




    Magnespasmyl may be available in the countries listed below.


    Ingredient matches for Magnespasmyl



    Magnesium Lactate

    Magnesium Lactate is reported as an ingredient of Magnespasmyl in the following countries:


    • Belgium

    International Drug Name Search

    at No comments:

    Monday, 16 November 2009

    Eloxatin


    Eloxatin is a brand name of oxaliplatin, approved by the FDA in the following formulation(s):


    ELOXATIN (oxaliplatin - injectable; iv (infusion))



    • Manufacturer: SANOFI AVENTIS US

      Approval date: January 31, 2005

      Strength(s): 100MG/20ML (5MG/ML) [RLD][AP], 50MG/10ML (5MG/ML) [RLD][AP]


    • Manufacturer: SANOFI AVENTIS US

      Approval date: November 17, 2006

      Strength(s): 200MG/40ML (5MG/ML) [RLD]

    Has a generic version of Eloxatin been approved?


    A generic version of Eloxatin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Eloxatin and have been approved by the FDA:


    oxaliplatin injectable; iv (infusion)



    • Manufacturer: EBEWE PHARMA

      Approval date: August 7, 2009

      Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]


    • Manufacturer: FRESENIUS KABI ONCOL

      Approval date: June 10, 2010

      Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]


    • Manufacturer: HOSPIRA WORLDWIDE

      Approval date: August 7, 2009

      Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]


    • Manufacturer: SANDOZ

      Approval date: January 24, 2011

      Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]


    • Manufacturer: TEVA PARENTERAL

      Approval date: August 7, 2009

      Strength(s): 100MG/20ML (5MG/ML) [AP], 50MG/10ML (5MG/ML) [AP]

    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eloxatin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Platinum compound and process of preparing same
      Patent 5,290,961
      Issued: March 1, 1994
      Inventor(s): Okamoto; Koji & Hoshi; Yuko & Nakanishi; Chihiro
      Assignee(s): Tanaka Kikinzoku Kogyo K.K.
      Disclosed herein are a platinum compound employed as raw material of medicines having carcinostatic effects, and a process of preparing the platinum compound. The platinum compound (I) substantially free from impurities can be prepared through a reaction between the corresponding dihalogen compound and an organic dibasic acid employing an iodine compound utilizing the difference of solubilities between the desired compound and the iodine compounds.
      Patent expiration dates:

      • January 12, 2013
        ✓ 
        Drug substance


      • July 12, 2013
        ✓ 
        Pediatric exclusivity




    • Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) having optically high purity
      Patent 5,338,874
      Issued: August 16, 1994
      Inventor(s): Nakanishi; Chihiro & Ohnishi; Yuko & Ohnishi; Junji & Taniuchi; Junichi & Okamoto; Koji & Tozawa; Takeshi
      Assignee(s): Tanaka Kikinzoku Kogyo K.K.
      Disclosed herein is cis-oxalato (trans-1-1,2-cyclohexanediamine) Pt(II) optically high purity. Because of its complete optical purity, the compound is effective as raw material of such a medicine as a carcinostatic agent. The complete optical purity of the above compound may be proved by comparing the respective melting points of the cis-oxalato (trans-1-1,2-cyclohexanediamine).
      Patent expiration dates:

      • April 7, 2013
        ✓ 
        Drug substance


      • October 7, 2013
        ✓ 
        Pediatric exclusivity




    • Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same
      Patent 5,420,319
      Issued: May 30, 1995
      Inventor(s): Okamoto; Koji & Nakanishi; Chihiro & Taniuchi; Junichi & Ohnishi; Junji & Komoda; Yasunobu
      Assignee(s): Tanaka Kikinzoku Kogyo K.K.
      Disclosed is cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and no toxicity and exhibiting anticancer performance, as shown in the below Formula. Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex of the invention possesses high optical purity or 99.94% or more e.e. and a melting point of 198.3.degree. to 199.7.degree. C. The complex is synthesized employing as starting material trans-1-1,2-cyclohexamediamine or a derivative of the trans-1-1,2-cyclohexanediamine optically resoluted by means of a high performance liquid chromatography. ##STR1##
      Patent expiration dates:

      • August 9, 2016
        ✓ 
        Drug substance


      • February 9, 2017
        ✓ 
        Pediatric exclusivity




    • Pharmaceutically stable preparation of oxaliplatinum
      Patent 5,716,988
      Issued: February 10, 1998
      Inventor(s): Ibrahim; Houssam & Mauvernay; Rolland-Yves
      Assignee(s): Debiopharm S.A.
      A pharmaceutically stable oxaliplatinum preparation for parenteral administration comprises an aqueous solution of oxaliplatinum, in a concentration of 1 to 5 mg/ml, and with a pH in the range of 4.5 to 6. The aqueous oxaliplatinum solution is advantageously provided as a ready-to-use preparation in a sealed container.
      Patent expiration dates:

      • August 7, 2015
        ✓ 
        Drug product


      • February 7, 2016
        ✓ 
        Pediatric exclusivity



    Related Exclusivities

    Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

    • Exclusivity expiration dates:
      • July 10, 2010 - PEDIATRIC EXCLUSIVITY

    See also...

    • Eloxatin Consumer Information (Drugs.com)
    • Eloxatin Consumer Information (Wolters Kluwer)
    • Eloxatin Consumer Information (Cerner Multum)
    • Eloxatin Advanced Consumer Information (Micromedex)
    • Eloxatin AHFS DI Monographs (ASHP)
    • Oxaliplatin Consumer Information (Wolters Kluwer)
    • Oxaliplatin Consumer Information (Cerner Multum)
    • Oxaliplatin Intravenous Advanced Consumer Information (Micromedex)
    • Oxaliplatin AHFS DI Monographs (ASHP)
    at No comments:

    Nebivolol AAA




    Nebivolol AAA may be available in the countries listed below.


    Ingredient matches for Nebivolol AAA



    Nebivolol

    Nebivolol hydrochloride (a derivative of Nebivolol) is reported as an ingredient of Nebivolol AAA in the following countries:


    • Germany

    International Drug Name Search

    at No comments:

    Friday, 13 November 2009

    Erilin




    Erilin may be available in the countries listed below.


    Ingredient matches for Erilin



    Sildenafil

    Sildenafil citrate (a derivative of Sildenafil) is reported as an ingredient of Erilin in the following countries:


    • Colombia

    International Drug Name Search

    at No comments:

    Sunday, 8 November 2009

    Cefonicid Sodium




    Cefonicid Sodium may be available in the countries listed below.


    Ingredient matches for Cefonicid Sodium



    Cefonicid

    Cefonicid Sodium (BANM, USAN) is known as Cefonicid in the US.

    International Drug Name Search

    Glossary

    BANMBritish Approved Name (Modified)
    USANUnited States Adopted Name

    Click for further information on drug naming conventions and International Nonproprietary Names.
    at No comments:

    Saturday, 7 November 2009

    Embeda


    Embeda is a brand name of morphine/naltrexone, approved by the FDA in the following formulation(s):


    EMBEDA (morphine sulfate; naltrexone hydrochloride - capsule, extended release; oral)



    • Manufacturer: ALPHARMA KING

      Approval date: August 13, 2009

      Strength(s): 100MG;4MG [RLD], 20MG;0.8MG, 30MG;1.2MG, 50MG;2MG, 60MG;2.4MG, 80MG;3.2MG

    Has a generic version of Embeda been approved?


    No. There is currently no therapeutically equivalent version of Embeda available.


    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Embeda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Pharmaceutical composition
      Patent 7,682,633
      Issued: March 23, 2010
      Inventor(s): Matthews; Frank & Boehm; Garth & Tang; Lijuan & Liang; Alfred
      Assignee(s): Alpharma Pharmaceuticals, LLC
      Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
      Patent expiration dates:

      • June 19, 2027
        ✓ 
        Patent use: MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME




    • Pharmaceutical compositions
      Patent 7,682,634
      Issued: March 23, 2010
      Inventor(s): Matthews; Frank & Boehm; Garth & Tang; Lijuan & Liang; Alfred
      Assignee(s): Alpharma Pharmaceuticals, LLC
      Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided.
      Patent expiration dates:

      • June 19, 2027
        ✓ 
        Drug product




    • Sequestering subunit and related compositions and methods
      Patent 7,815,934
      Issued: October 19, 2010
      Inventor(s): Boehm; Garth
      Assignee(s): Alpharma Pharmaceuticals, LLC
      A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit and a therapeutic agent in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
      Patent expiration dates:

      • December 12, 2027
        ✓ 
        Drug product



    Related Exclusivities

    Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

    • Exclusivity expiration dates:
      • August 13, 2012 - NEW COMBINATION

    See also...

    • Embeda Consumer Information (Drugs.com)
    • Embeda Extended-Release Capsules Consumer Information (Wolters Kluwer)
    • Embeda Consumer Information (Cerner Multum)
    • Embeda Advanced Consumer Information (Micromedex)
    • Morphine/Naltrexone Extended-Release Capsules Consumer Information (Wolters Kluwer)
    • Morphine and naltrexone Consumer Information (Cerner Multum)
    • Morphine and naltrexone Advanced Consumer Information (Micromedex)
    at No comments:

    Sunday, 1 November 2009

    Zopiclona Genfar




    Zopiclona Genfar may be available in the countries listed below.


    Ingredient matches for Zopiclona Genfar



    Eszopiclone

    Zopiclone is reported as an ingredient of Zopiclona Genfar in the following countries:


    • Colombia

    International Drug Name Search

    at No comments:

    Monday, 26 October 2009

    Itraconazol-Mepha




    Itraconazol-Mepha may be available in the countries listed below.


    Ingredient matches for Itraconazol-Mepha



    Itraconazole

    Itraconazole is reported as an ingredient of Itraconazol-Mepha in the following countries:


    • Switzerland

    International Drug Name Search

    at No comments:

    Wednesday, 21 October 2009

    Gado-MRT-ratiopharm




    Gado-MRT-ratiopharm may be available in the countries listed below.


    Ingredient matches for Gado-MRT-ratiopharm



    Gadopentetic Acid

    Gadopentetic Acid dimeglumine (a derivative of Gadopentetic Acid) is reported as an ingredient of Gado-MRT-ratiopharm in the following countries:


    • Germany

    International Drug Name Search

    at No comments:

    Monday, 19 October 2009

    Grifocriptina




    Grifocriptina may be available in the countries listed below.


    Ingredient matches for Grifocriptina



    Bromocriptine

    Bromocriptine mesilate (a derivative of Bromocriptine) is reported as an ingredient of Grifocriptina in the following countries:


    • Chile

    International Drug Name Search

    at No comments:

    Saturday, 10 October 2009

    Vitamin B12 Leciva




    Vitamin B12 Leciva may be available in the countries listed below.


    Ingredient matches for Vitamin B12 Leciva



    Cyanocobalamin

    Cyanocobalamin is reported as an ingredient of Vitamin B12 Leciva in the following countries:


    • Czech Republic

    • Slovakia

    International Drug Name Search

    at No comments:

    Wednesday, 7 October 2009

    Ticlodin




    Ticlodin may be available in the countries listed below.


    Ingredient matches for Ticlodin



    Ticlopidine

    Ticlopidine is reported as an ingredient of Ticlodin in the following countries:


    • Romania

    International Drug Name Search

    at No comments:

    Thursday, 24 September 2009

    Ask pH8




    Ask pH8 may be available in the countries listed below.


    Ingredient matches for Ask pH8



    Aspirin

    Acetylsalicylic Acid is reported as an ingredient of Ask pH8 in the following countries:


    • Serbia

    International Drug Name Search

    at No comments:

    Isordil


    Isordil is a brand name of isosorbide dinitrate, approved by the FDA in the following formulation(s):


    ISORDIL (isosorbide dinitrate - tablet; oral)



    • Manufacturer: VALEANT INTL

      Approval date: July 29, 1988

      Strength(s): 10MG [AB], 20MG [AB], 30MG [RLD][AB], 40MG [RLD], 5MG [AB]

    Has a generic version of Isordil been approved?


    Yes. The following products are equivalent to Isordil:


    isosorbide dinitrate tablet; oral



    • Manufacturer: PAR PHARM

      Approval date: March 12, 1987

      Strength(s): 10MG [AB], 5MG [AB]


    • Manufacturer: PAR PHARM

      Approval date: October 2, 1987

      Strength(s): 20MG [AB]


    • Manufacturer: PAR PHARM

      Approval date: January 12, 1988

      Strength(s): 30MG [AB]


    • Manufacturer: SANDOZ

      Approval date: January 7, 1988

      Strength(s): 10MG [AB], 5MG [AB]


    • Manufacturer: SANDOZ

      Approval date: April 7, 1988

      Strength(s): 20MG [AB]


    • Manufacturer: WATSON LABS

      Approval date: January 6, 1988

      Strength(s): 5MG [AB]


    • Manufacturer: WATSON LABS

      Approval date: January 7, 1988

      Strength(s): 10MG [AB]


    • Manufacturer: WEST WARD

      Approval date: October 29, 1987

      Strength(s): 10MG [AB], 5MG [AB]


    • Manufacturer: WEST WARD

      Approval date: November 2, 1987

      Strength(s): 20MG [AB]


    • Manufacturer: WEST WARD

      Approval date: January 10, 2007

      Strength(s): 30MG [AB]

    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Isordil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents

    There are no current U.S. patents associated with Isordil.

    See also...

    • Isordil Advanced Consumer Information (Micromedex)
    • Isosorbide Dinitrate Consumer Information (Wolters Kluwer)
    • Isosorbide Dinitrate Extended-Release Consumer Information (Wolters Kluwer)
    • Isosorbide dinitrate Consumer Information (Cerner Multum)
    • Apo-Isdn Advanced Consumer Information (Micromedex)
    • Isosorbide dinitrate Oral, Sublingual Advanced Consumer Information (Micromedex)
    at No comments:

    Monday, 21 September 2009

    Clometocillin




    Scheme

    Rec.INN

    ATC (Anatomical Therapeutic Chemical Classification)

    J01CE07

    CAS registry number (Chemical Abstracts Service)

    0001926-49-4

    Chemical Formula

    C17-H18-Cl2-N2-O5-S

    Molecular Weight

    433

    Therapeutic Category

    Antibacterial: Penicillin, penicillinase-sensitive

    Chemical Name

    4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[(3,4-dichlorophenyl)methoxyacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2α,5α,6ß)]-

    Foreign Names

    • Clometocillinum (Latin)
    • Clometocillin (German)
    • Clométocilline (French)
    • Clometocilina (Spanish)

    Generic Names

    • Clométocilline (OS: DCF)
    • Penicilline 356 (IS)

    Brand Names

    • Rixapen
      Menarini, Belgium; Menarini, Luxembourg

    International Drug Name Search

    Glossary

    DCFDénomination Commune Française
    ISInofficial Synonym
    OSOfficial Synonym
    Rec.INNRecommended International Nonproprietary Name (World Health Organization)

    Click for further information on drug naming conventions and International Nonproprietary Names.
    at No comments:

    Sunday, 20 September 2009

    Honguil




    Honguil may be available in the countries listed below.


    Ingredient matches for Honguil



    Fluconazole

    Fluconazole is reported as an ingredient of Honguil in the following countries:


    • Argentina

    Tioconazole

    Tioconazole is reported as an ingredient of Honguil in the following countries:


    • Argentina

    International Drug Name Search

    at No comments:

    Friday, 18 September 2009

    Satil




    Satil may be available in the countries listed below.


    Ingredient matches for Satil



    Sertraline

    Sertraline hydrochloride (a derivative of Sertraline) is reported as an ingredient of Satil in the following countries:


    • Venezuela

    International Drug Name Search

    at No comments:

    Monday, 14 September 2009

    Zesulan




    Zesulan may be available in the countries listed below.


    Ingredient matches for Zesulan



    Mequitazine

    Mequitazine is reported as an ingredient of Zesulan in the following countries:


    • Japan

    International Drug Name Search

    at No comments:

    Sunday, 6 September 2009

    Subroxine




    Subroxine may be available in the countries listed below.


    Ingredient matches for Subroxine



    Roxithromycin

    Roxithromycin is reported as an ingredient of Subroxine in the following countries:


    • France

    International Drug Name Search

    at No comments:

    Bepreve


    Bepreve is a brand name of bepotastine ophthalmic, approved by the FDA in the following formulation(s):


    BEPREVE (bepotastine besilate - solution/drops; ophthalmic)



    • Manufacturer: ISTA PHARMS

      Approval date: September 8, 2009

      Strength(s): 1.5% [RLD]

    Has a generic version of Bepreve been approved?


    No. There is currently no therapeutically equivalent version of Bepreve available.


    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bepreve. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Acid addition salt of optically active piperidine compound and process for preparing the same
      Patent 6,780,877
      Issued: August 24, 2004
      Inventor(s): Jun-ichiro; Kita & Hiroshi; Fujiwara & Shinji; Takamura
      Assignee(s): Ube Industries, Ltd.
      Tanabe Seiyaku Co., Ltd.
      The present invention is to provide a benzenesulfonic acid salt and a benzoic acid salt of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid represented by the formula (I): wherein * represents an asymmetric carbon, which are excellent in antihistaminic activity and anti-allergic activity, and a process for producing the same.
      Patent expiration dates:

      • December 25, 2017
        ✓ 
        Drug substance
        ✓ 
        Drug product



    Related Exclusivities

    Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

    • Exclusivity expiration dates:
      • September 8, 2014 - NEW CHEMICAL ENTITY

    See also...

    • Bepreve Consumer Information (Drugs.com)
    • Bepreve Eye Drops Consumer Information (Wolters Kluwer)
    • Bepreve Consumer Information (Cerner Multum)
    • Bepreve Advanced Consumer Information (Micromedex)
    • Bepreve AHFS DI Monographs (ASHP)
    • Bepotastine Eye Drops Consumer Information (Wolters Kluwer)
    • Bepotastine ophthalmic Consumer Information (Cerner Multum)
    • Bepotastine besilate Ophthalmic Advanced Consumer Information (Micromedex)
    • Bepotastine Besilate AHFS DI Monographs (ASHP)
    at No comments:

    Wednesday, 2 September 2009

    Coversyl




    Coversyl may be available in the countries listed below.


    Ingredient matches for Coversyl



    Perindopril

    Perindopril is reported as an ingredient of Coversyl in the following countries:


    • Aruba

    • Bahamas

    • Bahrain

    • Bangladesh

    • Barbados

    • Bermuda

    • Cayman Islands

    • Colombia

    • Egypt

    • Ghana

    • Greece

    • Grenada

    • Guyana

    • Iraq

    • Ireland

    • Jamaica

    • Jordan

    • Kuwait

    • Lebanon

    • Mexico

    • Netherlands Antilles

    • Nigeria

    • Oman

    • Qatar

    • Saint Lucia

    • Saint Vincent & The Grenadines

    • Saudi Arabia

    • Singapore

    • Sri Lanka

    • Sudan

    • Syria

    • Thailand

    • Trinidad & Tobago

    • Tunisia

    • Turkey

    • United Arab Emirates

    • Yemen

    Perindopril arginine (a derivative of Perindopril) is reported as an ingredient of Coversyl in the following countries:


    • Australia

    • France

    • Italy

    • Netherlands

    • Oman

    • Portugal

    • South Africa

    Perindopril erbumine (a derivative of Perindopril) is reported as an ingredient of Coversyl in the following countries:


    • Belgium

    • Brazil

    • Canada

    • Chile

    • Costa Rica

    • Dominican Republic

    • El Salvador

    • Guatemala

    • Honduras

    • Iceland

    • India

    • Japan

    • Malaysia

    • Malta

    • Myanmar

    • Netherlands

    • New Zealand

    • Nicaragua

    • Panama

    • Philippines

    • South Africa

    • Spain

    • Venezuela

    • Vietnam

    International Drug Name Search

    at No comments:

    Monday, 31 August 2009

    Carbicalcin




    Carbicalcin may be available in the countries listed below.


    Ingredient matches for Carbicalcin



    Elcatonin

    Elcatonin is reported as an ingredient of Carbicalcin in the following countries:


    • Spain

    International Drug Name Search

    at No comments:

    Sunday, 23 August 2009

    Synphase




    Synphase may be available in the countries listed below.


    UK matches:

    • Synphase Tablets
    • Synphase Tablets (SPC)

    Ingredient matches for Synphase



    Ethinylestradiol

    Ethinylestradiol is reported as an ingredient of Synphase in the following countries:


    • United Kingdom

    Norethisterone

    Norethisterone is reported as an ingredient of Synphase in the following countries:


    • United Kingdom

    International Drug Name Search

    Glossary

    SPC Summary of Product Characteristics (UK)

    Click for further information on drug naming conventions and International Nonproprietary Names.
    at No comments:

    Friday, 21 August 2009

    Carvedilol PCH




    Carvedilol PCH may be available in the countries listed below.


    Ingredient matches for Carvedilol PCH



    Carvedilol

    Carvedilol is reported as an ingredient of Carvedilol PCH in the following countries:


    • Netherlands

    International Drug Name Search

    at No comments:

    Tuesday, 18 August 2009

    Perazine




    ATC (Anatomical Therapeutic Chemical Classification)

    N05AB10

    CAS registry number (Chemical Abstracts Service)

    0000084-97-9

    Chemical Formula

    C20-H25-N3-S

    Molecular Weight

    339

    Therapeutic Category

    Neuroleptic

    Chemical Name

    10H-Phenothiazine, 10-[3-(4-methyl-1-piperazinyl)propyl]-

    Foreign Name

    • Perazin (German)

    Generic Name

    • P 725 (IS)

    Brand Names

    • Peragal
      Galena, Poland


    • Perazin
      Hasco, Poland


    • Perazin-neuraxpharm
      Neuraxpharm, Germany


    • Pernazinum
      Labor, Poland


    • Taxilan
      Lundbeck, Germany

    International Drug Name Search

    Glossary

    ISInofficial Synonym

    Click for further information on drug naming conventions and International Nonproprietary Names.
    at No comments:

    Tuesday, 11 August 2009

    Articadent




    In the US, Articadent (articaine/epinephrine systemic) is a member of the drug class local injectable anesthetics and is used to treat Anesthesia and Local Anesthesia.

    US matches:

    • Articadent

    Ingredient matches for Articadent



    Articaine

    Articaine hydrochloride (a derivative of Articaine) is reported as an ingredient of Articadent in the following countries:


    • France

    Epinephrine

    Epinephrine bitartrate (a derivative of Epinephrine) is reported as an ingredient of Articadent in the following countries:


    • France

    International Drug Name Search

    at No comments:

    Tamsulosina Normon




    Tamsulosina Normon may be available in the countries listed below.


    Ingredient matches for Tamsulosina Normon



    Tamsulosin

    Tamsulosin hydrochloride (a derivative of Tamsulosin) is reported as an ingredient of Tamsulosina Normon in the following countries:


    • Spain

    International Drug Name Search

    at No comments:

    Monday, 10 August 2009

    Veraptin




    Veraptin may be available in the countries listed below.


    Ingredient matches for Veraptin



    Verapamil

    Verapamil hydrochloride (a derivative of Verapamil) is reported as an ingredient of Veraptin in the following countries:


    • Italy

    International Drug Name Search

    at No comments:

    Amicacina Braun




    Amicacina Braun may be available in the countries listed below.


    Ingredient matches for Amicacina Braun



    Amikacin

    Amikacin sulfate (a derivative of Amikacin) is reported as an ingredient of Amicacina Braun in the following countries:


    • Spain

    International Drug Name Search

    at No comments:

    Friday, 7 August 2009

    Lipitor


    Lipitor is a brand name of atorvastatin, approved by the FDA in the following formulation(s):


    LIPITOR (atorvastatin calcium - tablet; oral)



    • Manufacturer: PFIZER

      Approval date: December 17, 1996

      Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB]


    • Manufacturer: PFIZER

      Approval date: April 7, 2000

      Strength(s): EQ 80MG BASE [RLD][AB]

    Has a generic version of Lipitor been approved?


    A generic version of Lipitor has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Lipitor and have been approved by the FDA:


    atorvastatin calcium tablet; oral



    • Manufacturer: RANBAXY LABS LTD

      Approval date: November 30, 2011

      Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 40MG BASE [AB], EQ 80MG BASE [AB]

    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lipitor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Stable oral CI-981 formulation and process of preparing same
      Patent 5,686,104
      Issued: November 11, 1997
      Inventor(s): Mills; Nancy & Muhammad; Nouman A. & Weiss; Jay & Nesbitt; Russell U.
      Assignee(s): Warner-Lambert Company
      An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.
      Patent expiration dates:

      • November 11, 2014
        ✓ 
        Patent use: METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
        ✓ 
        Drug product


      • May 11, 2015
        ✓ 
        Patent use: METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA
        ✓ 
        Pediatric exclusivity




    • Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
      Patent 5,969,156
      Issued: October 19, 1999
      Inventor(s): Briggs; Christopher A. & Jennings; Rex A. & Wade; Robert & Harasawa; Kikuko & Ichikawa; Shigeru & Minohara; Kazuo & Nakagawa; Shinsuke
      Assignee(s): Warner-Lambert Company
      Crystalline forms of atorvastatin and hydrates thereof are useful hypolipidemic and hypocholesterolemic agents.
      Patent expiration dates:

      • July 8, 2016
        ✓ 
        Drug substance


      • January 8, 2017
        ✓ 
        Pediatric exclusivity




    • Stable oral CI-981 formulation and process for preparing same
      Patent 6,126,971
      Issued: October 3, 2000
      Inventor(s): Mills; Nancy & Muhammad; Nouman A. & Weiss; Jay & Nesbitt; Russell U.
      Assignee(s): Warner-Lambert Company
      An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.
      Patent expiration dates:

      • January 19, 2013
        ✓ 
        Drug product


      • July 19, 2013
        ✓ 
        Pediatric exclusivity



    See also...

    • Lipitor Consumer Information (Drugs.com)
    • Lipitor Consumer Information (Wolters Kluwer)
    • Lipitor Consumer Information (Cerner Multum)
    • Lipitor Advanced Consumer Information (Micromedex)
    • Lipitor AHFS DI Monographs (ASHP)
    • Atorvastatin Consumer Information (Drugs.com)
    • Atorvastatin Consumer Information (Wolters Kluwer)
    • Atorvastatin Consumer Information (Cerner Multum)
    • Atorvastatin Advanced Consumer Information (Micromedex)
    • Atorvastatin Calcium AHFS DI Monographs (ASHP)
    at No comments:

    Wednesday, 5 August 2009

    Wizol




    Wizol may be available in the countries listed below.


    Ingredient matches for Wizol



    Ketoconazole

    Ketoconazole is reported as an ingredient of Wizol in the following countries:


    • Indonesia

    International Drug Name Search

    at No comments:

    Monday, 27 July 2009

    Larimef




    Larimef may be available in the countries listed below.


    Ingredient matches for Larimef



    Mefloquine

    Mefloquine hydrochloride (a derivative of Mefloquine) is reported as an ingredient of Larimef in the following countries:


    • Myanmar

    International Drug Name Search

    at No comments:

    Friday, 24 July 2009

    Calcijex


    Calcijex is a brand name of calcitriol, approved by the FDA in the following formulation(s):


    CALCIJEX (calcitriol - injectable; injection)



    • Manufacturer: ABBOTT

      Approval date: September 25, 1986

      Strength(s): 0.001MG/ML [RLD][AP], 0.002MG/ML [RLD][AP]

    Has a generic version of Calcijex been approved?


    A generic version of Calcijex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Calcijex and have been approved by the FDA:


    calcitriol injectable; injection



    • Manufacturer: AKORN

      Approval date: January 29, 2008

      Strength(s): 0.001MG/ML [AP], 0.002MG/ML [AP]


    • Manufacturer: APP PHARMS

      Approval date: December 31, 2002

      Strength(s): 0.001MG/ML [AP], 0.002MG/ML [AP]


    • Manufacturer: FRESENIUS MEDCL

      Approval date: February 20, 2003

      Strength(s): 0.001MG/ML [AP], 0.002MG/ML [AP]


    • Manufacturer: LUITPOLD

      Approval date: September 26, 2003

      Strength(s): 0.001MG/ML [AP], 0.002MG/ML [AP]


    • Manufacturer: ROCKWELL MEDCL

      Approval date: September 17, 2003

      Strength(s): 0.001MG/ML [AP]


    • Manufacturer: SAGENT PHARMS

      Approval date: February 8, 2006

      Strength(s): 0.001MG/ML [AP]


    • Manufacturer: TEVA PARENTERAL

      Approval date: March 31, 2003

      Strength(s): 0.002MG/ML [AP]

    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Calcijex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents


    Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




    • Low oxygen content compositions of 1.alpha., 25-dihydroxycholecalciferol
      Patent 6,051,567
      Issued: April 18, 2000
      Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan
      Assignee(s): Abbott Laboratories
      The invention relates to stable aqueous formulations comprising 1.alpha., 25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
      Patent expiration dates:

      • August 2, 2019


      • February 2, 2020
        ✓ 
        Pediatric exclusivity




    • Low oxygen content compositions of 1.alpha., 25-dihydroxycholeclciferol
      Patent 6,265,392
      Issued: July 24, 2001
      Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan
      Assignee(s): Abbott Laboratories
      The invention relates to stable aqueous formulations comprising 1.alpha.,25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
      Patent expiration dates:

      • August 2, 2019


      • February 2, 2020
        ✓ 
        Pediatric exclusivity




    • Low oxygen content compostions of 1.alpha., 25-dihydroxycholecalciferol
      Patent 6,274,169
      Issued: August 14, 2001
      Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan & Hartmann; Kurt J. & Farmer; Randall M. & Oberdier; John P.
      Assignee(s): Abbott Laboratories
      The invention relates to stable compositions comprising 1.alpha., 25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
      Patent expiration dates:

      • August 2, 2019


      • February 2, 2020
        ✓ 
        Pediatric exclusivity



    See also...

    • Calcijex Solution Consumer Information (Wolters Kluwer)
    • Calcitriol Consumer Information (Wolters Kluwer)
    • Calcitriol Solution Consumer Information (Wolters Kluwer)
    • Calcitriol Consumer Information (Cerner Multum)
    • Calcitriol AHFS DI Monographs (ASHP)
    at No comments:

    Wednesday, 22 July 2009

    Chol-Spasmoletten




    Chol-Spasmoletten may be available in the countries listed below.


    Ingredient matches for Chol-Spasmoletten



    Hymecromone

    Hymecromone is reported as an ingredient of Chol-Spasmoletten in the following countries:


    • Germany

    International Drug Name Search

    at No comments:

    Cilate




    Cilate may be available in the countries listed below.


    Ingredient matches for Cilate



    Citalopram

    Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Cilate in the following countries:


    • South Africa

    International Drug Name Search

    at No comments:

    Monday, 20 July 2009

    Nilandron


    Nilandron is a brand name of nilutamide, approved by the FDA in the following formulation(s):


    NILANDRON (nilutamide - tablet; oral)



    • Manufacturer: SANOFI AVENTIS US

      Approval date: April 30, 1999

      Strength(s): 150MG [RLD]

    Has a generic version of Nilandron been approved?


    No. There is currently no therapeutically equivalent version of Nilandron available.


    Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nilandron. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

    See also: About generic drugs.




    Related Patents

    There are no current U.S. patents associated with Nilandron.

    See also...

    • Nilandron Consumer Information (Wolters Kluwer)
    • Nilandron Consumer Information (Cerner Multum)
    • Nilandron Advanced Consumer Information (Micromedex)
    • Nilandron AHFS DI Monographs (ASHP)
    • Nilutamide Consumer Information (Wolters Kluwer)
    • Nilutamide Consumer Information (Cerner Multum)
    • Nilutamide Advanced Consumer Information (Micromedex)
    • Nilutamide AHFS DI Monographs (ASHP)
    at No comments:

    Monday, 13 July 2009

    Uriflox




    Uriflox may be available in the countries listed below.


    Ingredient matches for Uriflox



    Norfloxacin

    Norfloxacin is reported as an ingredient of Uriflox in the following countries:


    • Ethiopia

    International Drug Name Search

    at No comments:

    Friday, 10 July 2009

    Glucare




    Glucare may be available in the countries listed below.


    Ingredient matches for Glucare



    Metformin

    Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Glucare in the following countries:


    • Oman

    International Drug Name Search

    at No comments:

    Thursday, 9 July 2009

    Zomig




    In the US, Zomig (zolmitriptan systemic) is a member of the drug class antimigraine agents and is used to treat Cyclic Vomiting Syndrome and Migraine.

    US matches:

    • Zomig

    • Zomig Spray

    • Zomig ZMT Disintegrating Tablets

    • Zomig nasal

    • Zomig-ZMT

    • Zomig Nasal Spray

    UK matches:

    • Zomig Tablets 2.5mg
    • Zomig 5mg Nasal Spray
    • Zomig Rapimelt 2.5mg
    • Zomig Rapimelt 5mg Orodispersible Tablets
    • Zomig Tablets 2.5mg (SPC)
    • Zomig 5mg Nasal Spray (SPC)
    • Zomig Rapimelt 2.5mg (SPC)
    • Zomig Rapimelt 5 mg Orodispersible Tablets (SPC)

    Ingredient matches for Zomig



    Zolmitriptan

    Zolmitriptan is reported as an ingredient of Zomig in the following countries:


    • Aruba

    • Australia

    • Austria

    • Bahamas

    • Barbados

    • Belgium

    • Bermuda

    • Brazil

    • Canada

    • Costa Rica

    • Croatia (Hrvatska)

    • Czech Republic

    • Denmark

    • Dominican Republic

    • El Salvador

    • Estonia

    • Finland

    • France

    • Georgia

    • Ghana

    • Guatemala

    • Haiti

    • Hong Kong

    • Hungary

    • Iceland

    • Ireland

    • Israel

    • Italy

    • Jamaica

    • Japan

    • Kenya

    • Latvia

    • Lithuania

    • Luxembourg

    • Malawi

    • Malta

    • Mexico

    • Mozambique

    • Netherlands

    • Netherlands Antilles

    • Nicaragua

    • Nigeria

    • Norway

    • Oman

    • Panama

    • Philippines

    • Poland

    • Portugal

    • Russian Federation

    • Serbia

    • Singapore

    • Slovakia

    • Slovenia

    • South Africa

    • Spain

    • Sudan

    • Sweden

    • Switzerland

    • Tanzania

    • Thailand

    • Trinidad & Tobago

    • Turkey

    • Uganda

    • United Kingdom

    • United States

    • Zambia

    • Zimbabwe

    International Drug Name Search

    Glossary

    SPC Summary of Product Characteristics (UK)

    Click for further information on drug naming conventions and International Nonproprietary Names.
    at No comments:

    Vastoran




    Vastoran may be available in the countries listed below.


    Ingredient matches for Vastoran



    Pravastatin

    Pravastatin sodium salt (a derivative of Pravastatin) is reported as an ingredient of Vastoran in the following countries:


    • Australia

    International Drug Name Search

    at No comments: